Catégorie : Medtech

BLENDS

by jbertholdin Biotech, Institutions, Service Providers & others, Medtech, Pharma

BLENDS

About the company

Founded in 2023, Blends provides research intelligence for biotech companies and labs.

They deliver state-of-the-art systematic reviews within 24 hours using advanced methodologies, ensuring comprehensive and timely analysis that supports faster and more informed decision-making in research and development projects.

Their cutting-edge monitoring tools enhance productivity and effectiveness by offering real-time updates, enriched data, and unique insights into scientific developments. This includes features like Live, Reports, Trends, and Context, which transform how biotech information is accessed, analyzed, and applied, driving innovation and efficiency in the industry.

About the solution


Their cutting-edge monitoring tool is designed to keep researchers and labs fully informed about relevant scientific developments. It stands out with four main features: Live, Reports, Trends, and Context, each offering unique insights. Their platform enriches public data, providing summaries, key conclusions, importance indicators, and more, making research more exploitable than ever. Unlike competitors, their Context feature uniquely identifies analogies in unrelated research, fostering interdisciplinary breakthroughs.

Website
Key information

– Therapeutic areas: All therapeutic areas

– Based in: Versailles (FRANCE)

– Employees: 11 – 50

– Created in: 2023

AURORA STERILISATION

by jbertholdin Medtech

AURORA STERILISATION

About the company

Aurora was founded in 2019 by Jan Laarman and Thomas Parias, after 5 years of in-house industrial research, two entrepreneurs passionate about innovation in the field of healthcare. Their goal is to become a major player in the field of sterilization using natural plasma as the sole sterilizing agent.

About the solution

The company develops a unique patent-protected sterilization method based on an oxygen plasma. It enables the sterilization of complex and sensitive devices that can’t be sterilized with existing technologies. It operates at low temperature (30-40°C). It is an environmental-friendly sterilization technology of medical devices.

Website
Key information

–  Therapeutic areas: Endoscopy, Prosthetics, Sterilization

–  Based in: Rouen & Reims (FRANCE)

–  Employees: 11 – 50

–  Created in: 2019

RONDOL INDUSTRIE

by jbertholdin Biotech, Medtech, Pharma

RONDOL INDUSTRIE

About the company

Rondol Industrie have been created in 2012 with the goal of adapting hot melt extrusion technology to the micro scale and to Pharma standards, thereby contributing to better and cheaper healthcare.

Their team aims to leverage their combined 60 years of experience in extrusion technologies to offer a range of energy-efficient machines that would enable pharmaceutical companies to conduct trials and manufacture in better and cheaper formulations.

Along the way, they realized that their extrusion machines were capable of much more than initially expected. They can now produce a diverse range of extruded products via custom dies.

About the solution


Best of all, their vertical extruders are much smaller than traditional machines, saving on expensive footprint and material costs. Ease of cleaning also enables a quick turnaround between production lots or trials.

They are proud of what they have achieved so far – ground-breaking improvements in the bioavailability of aspirin for cancer treatment and reformulation of anti-malarial drugs to be suitable for children, among numerous other drug and medical implant trials. They are growing partnerships with industry and academia in Canada, England, France, Germany, Northern Ireland, and the USA. They have twice been nominated for a Galien Award in 2020 and 2023.

Website
Key information

–  Therapeutic areas: Hot Melt Extruders for Drug Formulation and Medical Device

–  Based in: Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2012

AGENT

by jbertholdin Medtech

AgenT

About the company

AgenT, founded in 2018, is on a mission to defeat Alzheimer’s by targeting the silent phase. Leveraging a groundbreaking multi-omics approach combined with A.I., they have identified new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they have developed two blood tests, B-HEALED™ and B-AHEAD™, for early and precise detection during the pre-dementia stages, unlocking the future of precision medicine. Their innovation is crucial in the era of emerging treatments like Leqembi, enabling detection and treatment of Alzheimer’s before cognitive decline manifests.

By embracing precision medicine and expanding the biomarker toolkit, AgenT is positioning themselves for the next leap in Alzheimer’s treatment, ensuring patients receive the right therapy at the right time.

About the solution


Traditional Alzheimer’s tests detect brain amyloid levels—a risk factor, not a definitive diagnostic marker, leading to up to 25% false positives among mild cognitive impairment (MCI) patients. AgenT’s B-HEALED test dramatically reduces this false positive rate by two-thirds with its non-invasive, cost-effective, and scalable blood test, offering a breakthrough in Alzheimer’s diagnostics.

By accurately identifying MCI patients who can benefit from early intervention with disease-modifying treatments, their test ensures timely and precise therapy to slow Alzheimer’s progression effectively, without exposing non-Alzheimer’s patients to unnecessary drug side effects.

Website
Key information

–  Therapeutic areas: Alzheimer’s Disease, CNS

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2018

CARTHERA

by jbertholdin Medtech

CARTHERA

About the company

Carthera is a clinical-stage company developing the SonoCloud, a revolutionary system to temporarily open the blood-brain barrier (BBB), and to improve CNS bioavailability of small molecules, ASOs, mAbs and other therapeutics. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases.

About the solution

SonoCloud is an intracranial implant using low-intensity pulsed ultrasound (LIPU) to temporarily open the blood-brain barrier BBB before or after the injection of therapeutics. This innovative approach is being tested in several clinical programs in Glioblastoma with different chemotherapeutic agents as well as PDL-1 & CTLA-4 antibodies. SonoCloud is now entering the neurodegeneration field with focus on ALS, Huntington Disease and Parkinson Disease.

Website
Key information

–  Therapeutic areas: Oncology, Neurodegenerative diseases

–  Based in: Lyon (FRANCE) Office in Boston (USA)

–  Employees: 11 – 50

–  Created in: 2010

BRAINTALE

by jbertholdin Digital Health, Medtech

BRAINTALE

About the company

BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.

BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients. 

About the solution

BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.

Website
Key information

–  Therapeutic areas: Neuroscience, Neurology, Alzheimer’s Disease, Multiple Sclerosis, Traumatic Brain Injury, Rare demyelinating diseases

–  Based in: Paris & Strasbourg (FRANCE)

–  Employees: 11 – 50

–  Created in: 2018

HERMERION THERAPEUTICS

by jbertholdin Biotech, Medtech, Pharma

HERMERION THERAPEUTICS

About the company

Hemerion was created in 2020, after more than 10 years of academic research carried out in an INSERM laboratory in association with Lille University Hospital in France. They are developing a first-line treatment for newly diagnosed Glioblastoma (GBM) that integrates with surgery before the administration of adjuvant therapies.

Their mission is to deliver novel therapies that aim at significantly improving the overall survival and quality of life of GBM patients.

Hemerion is an award-winning HealthTech company:

– In 2021 they received the Galien MedStartup Prize for « Best Collaboration in the MedTech and Digital Health » category. The Galien MedStartup fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of the most promising French startups, selected by a world-renowned panel, and connects them with leading American businesses.

– In 2023 they were awarded the Golden Ticket Ipsen Biolabs at the Biotech incubator Hotel Dieu Paris, granting them access to biology laboratories to enable the development of preclinical research in glioblastoma.

About the solution

They are developing a first-in-class therapeutic approach for glioblastoma (GBM), the most common malignant brain tumor in adults with 156,000 new cases worldwide per year. Their strategy is promising to significantly improve GBM care management through its unique properties:

– They combine a photonic device (Heliance® Solution) and a drug (Pentalafen®), a photosensitizing agent, which has a therapeutic effect when illuminated with red light.

– This approach represents a breakthrough one-time intervention enabling the destruction of residual tumor cells, responsible for tumor recurrence, following surgery resection.

– It is harmless for healthy tissues as Pentalafen® preferentially accumulates in tumor cells to selectively destroy them.

All in all, their innovation is a novel and safe mechanism of action significantly improving GBM upfront care management by only adding 30 minutes to the current care workflow. Their solution is a photodynamic therapy approach for GBM patients undergoing surgery and seamlessly fits into any patient continuum of care.

Website
Key information

–  Therapeutic areas: Oncology, Neuro-Oncology, Brain Tumor, Neurosurgery

–  Based in: Lille & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2020

ROSETTA OMICS

by jbertholdin Biotech, Medtech, Pharma

ROSETTA OMICS

About the company

Rosetta Omics pioneers precision medicine through tumor characterization using spatial multiomics, deep mass spectrometry and AI. Their focus is to optimize first-line treatments by matching therapies with patients effectively, starting with liver and colon cancers. They aim to empower oncologists with a transformative tool, enhancing patient care, and cutting costs. Collaborating with pharma and biotech firms, they seek to identify new biomarkers, accelerating therapeutic and diagnostic innovations.

Committed to scientific advancement and patient well-being, Rosetta Omics is reshaping cancer care. Through cutting-edge technologies and comprehensive multiomics analysis, they provide personalized treatment insights for improved outcomes. Rosetta Omics is at the forefront of precision medicine, driven by innovation, collaboration, and a commitment to saving lives.

About the solution

Their biopsy-based predictive test can be integrated within the standard clinical procedure of biopsy collection for diagnostics to assist in the decision-making process. Their services and products can also identify biomarkers of clinical interest and be used to discover new targets for drug development.

Website
Key information

–  Therapeutic areas: Oncology, Cancer, Liver cancer, Colon cancer, Precision medicine, AI

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2023